Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Matthew R. Porembka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1596-0058; OpenAlex author ID A5031442486. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers

Papers 15

  1. Post-operative patterns of failure and outcomes reveal opportunities to optimize treatment of recurrent pancreatic cancer Co-author DOI 10.1101/2025.11.08.25339815↗
  2. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  3. Minimally invasive pancreaticoduodenectomy: A favorable approach for frail patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.022↗
  4. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Co-author DOI 10.1002/jso.27357↗
  5. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  6. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Co-author DOI 10.1016/j.ijrobp.2022.07.019↗
  7. Clinicopathologic Features and Outcomes of Early-Onset Pancreatic Adenocarcinoma in the United States. Co-author DOI 10.1245/s10434-019-08096-y↗
  8. Comparison of Overall Survival Between Preoperative Chemotherapy and Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2018.7068↗
  9. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Co-author DOI 10.1200/jco.2016.68.5081↗
  10. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  11. Imaging comparison of tubular and colloid pancreatic adenocarcinoma arising from intraductal papillary mucinous neoplasm on multidetector CT. Co-author DOI 10.1016/j.clinimag.2016.08.011↗
  12. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Co-author DOI 10.1158/1078-0432.ccr-15-1883↗
  13. A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.4236/jct.2013.43096↗
  14. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Co-author DOI 10.1007/s00262-011-1178-0↗
  15. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Co-author DOI 10.2174/156800911796191024↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patricio Marcelo Polanco · 9 shared papers, 2017–2025 · strength 1.35
  2. Herbert J. Zeh · 7 shared papers, 2020–2025 · strength 1.20
  3. Adam Charles Yopp · 7 shared papers, 2017–2025 · strength 0.99
  4. Sam C. Wang · 7 shared papers, 2016–2024 · strength 0.86
  5. John C. Mansour · 6 shared papers, 2017–2025 · strength 0.81
  6. Nina Niu Sanford · 3 shared papers, 2022–2025 · strength 0.54
  7. Ahmed M. Elamir · 3 shared papers, 2022–2025 · strength 0.54
  8. Syed Mohammad Ali Kazmi · 3 shared papers, 2022–2025 · strength 0.54
  9. Todd Anthony Aguilera · 3 shared papers, 2022–2025 · strength 0.54
  10. Peter Q. Leung · 2 shared papers, 2025 · strength 0.41
  11. Salwan S. Al Mutar · 2 shared papers, 2025 · strength 0.41
  12. Gilbert Zvikomborero Murimwa · 2 shared papers, 2023 · strength 0.34
  13. Muhammad Shaalan Beg · 2 shared papers, 2022–2025 · strength 0.31
  14. Caitlin A. Hester · 2 shared papers, 2020–2023 · strength 0.28
  15. Megan Wachsmann · 2 shared papers, 2016–2025 · strength 0.24
  16. John Michael P. Tomagan · 1 shared paper, 2025 · strength 0.23
  17. Shahed Nicolas Badiyan · 1 shared paper, 2025 · strength 0.23
  18. Amr I. Al Abbas · 1 shared paper, 2024 · strength 0.21
  19. Emile Farah · 1 shared paper, 2024 · strength 0.21
  20. Zhikai Chi · 1 shared paper, 2025 · strength 0.18
  21. Ali A. Mokdad · 2 shared papers, 2017–2018 · strength 0.15
  22. Matteo Ligorio · 1 shared paper, 2022 · strength 0.13
  23. Ravikanth Maddipati · 1 shared paper, 2022 · strength 0.13
  24. Peter J. Allen · 2 shared papers, 2016 · strength 0.13
  25. Javier E. Ordonez · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.